Greenwood Capital Associates LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 8,442 shares of the biopharmaceutical company's stock, valued at approximately $5,354,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $25,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares in the last quarter. Tompkins Financial Corp acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, Curat Global LLC acquired a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.
Regeneron Pharmaceuticals Price Performance
Shares of REGN stock traded up $6.99 during mid-day trading on Friday, reaching $528.83. The company's stock had a trading volume of 629,864 shares, compared to its average volume of 874,001. The firm's 50-day moving average is $563.74 and its two-hundred day moving average is $651.53. The company has a market cap of $57.09 billion, a P/E ratio of 13.80, a PEG ratio of 2.34 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the company earned $9.55 EPS. The business's revenue for the quarter was down 3.7% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on REGN. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a report on Monday, June 2nd. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group cut their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $836.48.
Check Out Our Latest Stock Analysis on REGN
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Articles
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
